Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
61
Language
English
Published on
31/01/25
You may also be interested by these reports :
07/02/25
Supported by ongoing operational improvements, Emeis delivered FY24 results ahead of guidance and provided above-consensus FY25 guidance. While the ...
07/02/25
GN’s Q4 results met market expectations. Healthy growth in the Hearing segment was counterbalanced by a weaker performance in Gaming & Consumer and ...
07/02/25
Healthineers reported a solid performance in Q1, surpassing consensus expectations with sales up +2.1%, adjusted EBIT up +2.5%, and net profit up ...
06/02/25
Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. ...